FIGO Staging for Cervical Cancer and Stage-Specific Management
Cervical cancer staging follows the FIGO classification system, which has been revised to incorporate imaging and lymph node assessment, with treatment ranging from conservative surgery for microinvasive disease to concurrent chemoradiation for locally advanced stages.
FIGO Staging Classification
Stage I: Tumor Confined to Cervix
Stage IA (Microinvasive):
- IA1: Stromal invasion ≤3.0 mm in depth and ≤7.0 mm horizontal spread 1
- IA2: Stromal invasion >3.0 mm but ≤5.0 mm with horizontal spread ≤7.0 mm 1
Stage IB (Clinically visible or microscopic lesion >IA2):
- IB1: Clinically visible lesion ≤4.0 cm in greatest dimension 1
- IB2: Clinically visible lesion >4.0 cm in greatest dimension 1
- Note: The 2018 FIGO revision subdivided IB further, with IB1 now representing tumors ≥5 mm and <2 cm, IB2 for 2-4 cm tumors, and IB3 for tumors ≥4 cm 2
Stage II: Tumor Invades Beyond Uterus
Stage IIA (No parametrial invasion):
Stage IIB: Tumor with parametrial invasion 1
Stage III: Extension to Pelvic Wall or Lower Vagina
Stage IIIA: Tumor involves lower third of vagina 1
Stage IIIB: Tumor extends to pelvic wall or causes hydronephrosis/non-functioning kidney 1
Stage IIIC (2018 revision): Lymph node involvement
Stage IV: Distant Spread
Stage IVA: Tumor invades bladder or rectal mucosa, or extends beyond true pelvis 1
Stage IVB: Distant metastasis (including inguinal lymph nodes and intraperitoneal disease) 1
Stage-Specific Management
Stage IA1 (Without LVSI)
Primary Treatment:
- Conization or simple trachelectomy for fertility preservation with negative margins 1
- Simple hysterectomy for patients not desiring fertility 1
- Observation acceptable if negative margins after cone biopsy and patient refuses surgery 3
Stage IA1 (With LVSI):
- Modified radical hysterectomy with sentinel lymph node (SLN) mapping or pelvic lymph node dissection 3
- Simple hysterectomy + pelvic lymph node dissection ± para-aortic lymph node dissection 1
Stage IA2
Fertility-Sparing Options:
- Radical trachelectomy with pelvic lymph node dissection (SLN mapping can be considered) 3
- Cone biopsy with observation if negative margins and negative pelvic lymph node dissection 3
Non-Fertility-Sparing:
- Radical hysterectomy with bilateral pelvic lymph node dissection (± para-aortic lymph node dissection) 3
- SLN mapping can be considered 3
- Pelvic external beam radiation therapy (EBRT) with brachytherapy (70-80 Gy to point A) for medically inoperable patients or those refusing surgery 3
Stage IB1 and IIA1
Fertility-Sparing (IB1 only):
- Radical trachelectomy with pelvic lymph node dissection (± para-aortic lymph node dissection) for tumors ≤2 cm 3
- SLN mapping can be considered 3
- Tumors 2-4 cm must be carefully selected due to risk of requiring adjuvant therapy 3
- Contraindications: Small cell neuroendocrine histology, gastric-type adenocarcinoma, adenoma malignum 3
Non-Fertility-Sparing:
- Radical hysterectomy with bilateral pelvic lymph node dissection (± para-aortic lymph node dissection) - Category 1 recommendation 3, 1
- SLN mapping can be considered 3, 1
- Para-aortic node dissection indicated for known or suspected pelvic nodal disease 3
- Surgery can be performed via laparotomy or minimally invasive approach (laparoscopy/robotic) 1
- Alternative: Concurrent chemoradiation for medically inoperable patients 3
Stage IB2 and IIA2
Primary Treatment:
- Concurrent chemoradiation - Category 1 recommendation (preferred over primary surgery based on randomized trials) 3
- Pelvic EBRT with brachytherapy plus concurrent cisplatin-based chemotherapy 3
Alternative Approach:
- Primary radical hysterectomy with bilateral pelvic lymph node dissection (± para-aortic lymph node dissection) 3
- PET/CT scan recommended before treatment to rule out extrapelvic disease 3
- Radiologic imaging recommended for assessing tumor extent 3
Stage IIB, III, and IVA (Locally Advanced Disease)
Primary Treatment:
- Concurrent chemoradiation with pelvic EBRT and brachytherapy 3, 1
- Tailoring of radiation according to surgical staging or PET-CT findings 1
- Neoadjuvant chemotherapy followed by surgery or radiation therapy is an option 1
- Pelvic exenteration may be considered for select Stage IVA patients 1
Stage IVB (Metastatic Disease)
Preferred Regimens:
- Cisplatin/paclitaxel/bevacizumab - Category 1 3
- Carboplatin/paclitaxel/bevacizumab 3
- Topotecan/paclitaxel/bevacizumab 3
Alternative Regimens:
- Cisplatin/paclitaxel (Category 1) 3
- Carboplatin/paclitaxel (Category 1 for patients with prior cisplatin therapy) 3
- Topotecan/paclitaxel 3
Palliative radiation therapy for symptomatic disease 1
Important Clinical Considerations
Sentinel Lymph Node Mapping
- Should be considered for Stage IA2, IB1, and IIA1 disease 3, 1
- Detection rate highest for tumors <2 cm 1
- Requires adequate center expertise and training 1
- Tracer injected directly into cervix (blue dye, technetium radiocolloid, or indocyanine green) 1
Adjuvant Treatment After Surgery
- Depends on pathologic risk factors including positive margins, lymph node involvement, parametrial invasion, and Sedlis criteria (tumor size, depth of invasion, lymphovascular space invasion) 3
- Patients meeting high-risk criteria require postoperative chemoradiation 3
Imaging for Advanced Disease
- PET/CT has 53-73% sensitivity and 90-97% specificity for lymph node involvement in early-stage disease 1
- Sensitivity increases to 75% with 95% specificity for para-aortic nodes in advanced stages 1
Common Pitfalls
- Avoid minimally invasive surgery for bulky IB2 tumors - concurrent chemoradiation is the Category 1 recommendation 3
- Do not use fertility-sparing surgery for unfavorable histologies (small cell neuroendocrine, gastric-type adenocarcinoma) 3
- Ensure adequate surgical expertise before performing SLN mapping 1
- Document staging method used (clinical, imaging, or surgical) as the revised FIGO system does not mandate a specific method 2